Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
Expression of cells a mutant CDK4 (CDK4(R24C)) in beta-cells enhanced beta-cell replication. CDK4(R24C) also dampened compensatory beta-cell neogenesis in larvae and improved glucose tolerance in adult zebrafish.
study highlights the importance of the CDK4/6-Rb pathway in human synovial sarcoma pathogenesis, and the role of the current selective CDK4/6 inhibitor, palbociclib, as a potential promising targeted therapeutic agent in the treatment of human synovial sarcoma.
these studies identify MAPK reliance in acquired CDK4/6 inhibitor resistance that promotes aggressive disease, while nominating MEK inhibition as putative novel therapeutic strategy to treat or prevent CDK4/6 inhibitor resistance in cancer
These results demonstrate a novel regulatory axis of malignant cell proliferation and invasion in gastric cancer, comprising GCRL1, miR-885-3p, and CDK4.
The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB) protein phosphorylation.
analysis of glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification
we report the molecular studies of a familial case of cutaneous melanoma carrying the new germline mutation CDK4c.71G>T,p.Arg24Leu.
results reveal the role of hsa_circ_0016788/miR-486/CDK4 in hepatocellular carcinoma tumorigenesis, providing a novel therapeutic target for hepatocellular carcinoma
Study of 51 patients with extramammary Paget's disease (EMPD) revealed that almost all tissue samples were positive for CDK4, and metastatic lesions had a similar immunostaining intensity to primary lesions. In addition, CDK4 protein levels were positively correlated with those of cyclin D1 protein. Taken together, CDK4 may assume a crucial role in EMPD progression.
The activation of c-Met/TrkA-B pathways is a novel mechanism involved in therapeutic resistance of GBM to CDK4/6 inhibition.
Inhibiting CDK4 abolished the ability of JMJD6 in enhancing cell proliferation.
The additional 4% diagnostic yield in non-CDKN2A/CDK4 families.
It is likely that CDK4/6 inhibitors will have a broader impact than their expected induction of cell cycle arrest in the treatment of human cancers
circ_0007766 can up-regulate the expression of Cyclin D1/Cyclin E1/CDK4, which are the key proteins of cell cycle, and thus promote the malignant proliferation of lung adenocarcinoma
bergapten significantly increased the subG1 phase ratio to ~9% (P<0.05) in the two cell types. Further investigation demonstrated that bergapten upregulated the expression of cellular tumor antigen p53 (p53) and its downstream proteins cyclindependent kinase inhibitor 1 and cyclindependent kinase inhibitor 1B, whereas, it downregulated the expression of cyclin D1 and CDK4
Combination treatment with MTOR and CDK4/6 inhibitors had potent activity across a large number of patient-derived models of PDAC underscoring the potential clinical efficacy.
Targeting of glutamine addiction and overcoming of CDK4/CDK6 antineoplastic drug resistance in human esophageal squamous cell carcinoma has been reported.
PFKFB3 is a hub for coordinating cell cycle and glucose metabolism. Combined targeting of PFKFB3 and CDK4 may be new strategy for breast cancer treatment.
circ_0025039 promotes cell growth, invasion and glucose metabolism in malignant melanoma by sponging miR-198 and regulating CDK4.
miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
the present study is the first to demonstrate that miR-338-3p functions as a tumor suppressor in multiple myeloma (MM)through inhibiting CDK4. This finding implies that miR-338-3p is a potential therapeutic target for the treatment of MM.
The in vitro cultivation of cumulus cells was associated with cell proliferation and that Cx43 and Cdk4 gene expression was upregulated after in vitro cultivation, resulting in significantly higher protein levels.
The authors' findings establish a firm molecular link of multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6 and identify CDK4/6 inhibitors as actionable drugs for controlling SCP3(high) immune-refractory cancer. These findings reveal cyclin D1-CDK4/6 inhibition as an effective strategy for controlling SCP3high immune-refractroy cancer.
DNA Damage Response in Proliferating Muller Glia in the Mammalian Retina.
CDK4/CDK6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.
Study examined proliferation rates of cortical progenitor cells in mice lacking individual cdk proteins or combinations thereof. Results provide evidence that concomitant loss of cdk4 and cdk6 leads to reduced proliferation rates specifically in basal progenitor cells in both the dorsal and ventral forebrain. Cdk4-/-;Cdk6-/- double mutant progenitor cells in the dorsal telencephalon exhibit accelerated cell cycle exit.
These results indicate that p18 blocks reprogramming by targeting Cdk4/6-mediated cell cycle regulation.
Activation of cdk4 triggers NAFLD.
This novel mechanism explains how CDK4 promotes anabolism by blocking catabolic processes (FAO) that are activated by AMPK.
PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration.
The results demonstrate a unique CDK4-mediated mitochondrial communication that allows cells to sense environmental genotoxic stress and boost mitochondrial homeostasis by enhancing phosphorylation and activation of MnSOD.
a crucial role of RXRa in suppression of UVB-induced melanomas in the context of driver mutations such as activated CDK4(R24C/R24C) or oncogenic NRAS(Q61K) and altered expression of p53 and PTEN
Our data indicate that Cdk2 and Cdk4 play important overlapping roles in homeostatic and stress hematopoiesis, which need to be considered when using broad-spectrum cyclin-dependent kinase inhibitors for cancer therapy.
CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.
Cdk4 and Cdk6 cooperate in hematopoietic tumor development and suggest a role for Cdk6 in sequestering INK4 proteins away from Cdk4.
CDK4 seems to be expressed as multiple proteins that respond differently to different shRNAs, and have previously unrecognized functions at the S-G 2/M phases of the cell cycle via mechanisms independent of binding to CCND and RB.
insulin activates cyclin D1-cyclin-dependent kinase 4 (Cdk4), which, in turn, increases GCN5 acetyltransferase activity and suppresses hepatic glucose production independently of cell cycle progression
CDK4 deficiency markedly accelerated lymphoma development in the Emu-Myc transgenic model of B lymphoma
Cdk4- and Arf-mutant mice exhibited similar profiles, the Trp53(F/F) ::Tyr-Cre(ER)::Tyr-NRAS melanomas were strikingly different, showing relative down-regulation of melanocyte-related genes, and up-regulation of genes related to neural differentiation.
A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases.
UCH-L1 physically interacts with CDK1, CDK4, and CDK5, enhancing their kinase activity.
Hesperetin prevented the xenograft growth by down-regulating the expression of cyclin D1, CDK4 and Bcl-xL and up-regulating p57Kip2 expression in MCF-7 cells.
CCND1 mRNA expression is increased by FGF9 in bovine theca cells and granulosa cells.
The results indicate that the precise regulation of neuronal Cdk4 activity is important to limit mitochondrial reactive oxygen species production and prevent neurodegeneration.
CDK4 activity regulates mitobiogenesis by the activation of NRF-1 and consequent induction of Tfam and mitochondrial ribossomal transcription.
Delg and cyclin D/Cdk4 have roles in nutritional control of mitochondrial biogenesis in the Drosophila adipose tissue
Cyclin D-cdk4 is not a master regulator of cell multiplication in Drosophila embryos
mRpL12 is required for CycD/Cdk4-induced cell growth
Our data suggest that the growth-specific function of CycD/Cdk4 is conserved from arthropods to mammals.
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.
cell division protein kinase 4
, cyclin dependent kinase 4
, serine/threonine kinase
, Cell division protein kinase 4
, Cyclin-dependent kinase 4/6
, cyclin-dependent kinase 4
, protein kinase-like 53C